awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q40301879-9DF84F7C-A00E-4357-A207-117A86E34895
Q40301879-9DF84F7C-A00E-4357-A207-117A86E34895
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40301879-9DF84F7C-A00E-4357-A207-117A86E34895
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
P2860
Q40301879-9DF84F7C-A00E-4357-A207-117A86E34895
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40301879-9DF84F7C-A00E-4357-A207-117A86E34895
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
82b8a72aff86c2b2f8dcff901bc0403993fb220e
P2860
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai